Company Overview - Rezolute, Inc. is a late-stage biopharmaceutical company focused on developing transformative therapies for rare diseases with significant unmet needs [1] - The company is particularly dedicated to improving outcomes for individuals suffering from hypoglycemia caused by hyperinsulinism (HI) [3] Leadership Appointment - Erik Harris has been appointed to the Board of Directors of Rezolute, effective immediately [1] - Mr. Harris is currently the Chief Commercial Officer and Executive Vice President at Ultragenyx, bringing over 20 years of biopharmaceutical expertise [1][2] - The CEO of Rezolute, Nevan Charles Elam, expressed enthusiasm about Mr. Harris's appointment, highlighting his experience in rare disease commercialization and strategic vision [2] Product Development - Rezolute's lead product, ersodetug, is an antibody therapy designed to treat all forms of hyperinsulinism and has shown substantial benefits in clinical trials [3] - The company aims to advance ersodetug through clinical development and prepare for potential commercialization [2][3]
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors